Top

Published in:

01-11-2010

Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy

Authors: Andrew M. Evens, Rupali Roy, Danielle Sterrenberg, Michelle Z. Moll, Amy Chadburn, Leo I. Gordon

Published in: Current Oncology Reports | Issue 6/2010

Abstract

Post-transplantation lymphoproliferative disorders (PTLD) are a heterogenous group of abnormal lymphoid proliferations that occur after solid organ transplant (SOT) or hematopoietic transplantation. PTLDs consist of a disease spectrum ranging from hyperplasia to aggressive lymphomas with 60–70% being Epstein–Barr virus positive. The majority of cases are B-cell, although 10–15% are of T-cell origin or rarely Hodgkin lymphoma. Recent SOT series suggest PTLD occurs at a median of 36–40 months after transplant. Clinically, extra-nodal disease is common (up to 75–85%) including CNS involvement, which is seen in 10–15% of all cases. Since the first report over 40 years ago, PTLD has remained one of the most morbid complications associated with SOT. However, recent data suggests improved survival in the modern era, especially with the integration of early rituximab-based therapy. These studies utilized first line rituximab (+/− chemotherapy) together with reduced immune suppression (RI) for monomorphic and polymorphic PTLD. It will be critical in future studies to determine which PTLDs are most amenable to initial therapy with RI alone, versus RI/rituximab, versus RI/rituximab/chemotherapy. Additionally, novel therapeutics, such as adoptive immunotherapy, should continue to be explored.

Penn I, Hammond W, Brettschneider L, Starzl TE: Malignant lymphomas in transplantation patients. Transplant Proc 1969, 1:106–112.PubMed

• Ghobrial IM, Habermann TM, Maurer MJ, et al.: Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005, 23:7574–7582. This is one of the largest PTLD series reported to date; the authors studied 107 patients over a 33-year period.

Leblond V, Dhedin N, Mamzer Bruneel MF, et al.: Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001, 19:772–778.PubMed

Nelson BP, Nalesnik MA, Bahler DW, et al.: Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000, 24:375–385.PubMedCrossRef

• Evens AM, David KA, Helenowski I, et al.: Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010, 28:1038–1046. This is a multicenter analysis of 80 PTLD patients treated over a recent 10-year period. There appeared to be significantly improved OS from early rituximab-based therapy.

•• Trappe R CS, Oertel S: Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD: Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial. Blood 2009, 100a. This is a recent presentation of a large prospective multicenter PTLD analysis that utilized early rituximab-based therapy. One-year PFS was 93% using risk-stratified therapy using R-CHOP for patients who did not achieve CR to 4 weeks of rituximab.

Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003, 31:145–155.PubMedCrossRef

Mamzer-Bruneel MF, Lome C, Morelon E, et al.: Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 2000, 18:3622–3632.PubMed

Leblond V, Davi F, Charlotte F, et al.: Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998, 16:2052–2059.PubMed

10.

Dotti G, Fiocchi R, Motta T, et al.: Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 2002, 74:1095–1102.PubMedCrossRef

11.

Elstrom RL, Andreadis C, Aqui NA, et al.: Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006, 6:569–576.PubMedCrossRef

12.

• Knight J, Tsodikov A, Cibrik D, et al.: Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009, 27:1–12. The authors examined 7040 patients who received SOT from 1964 to 2007, from which 78 patients developed PTLD. They assessed risk factors for development of PTLD and compared outcomes with a SEER population sample.

13.

• Maecker B, Jack T, Zimmermann M, et al.: CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007, 25:4902–4908. A total of 55 pediatric PTLD patients were studied. The 5-year EFS and OS were 59% and 68%, respectively.

14.

McDonald RA, Smith JM, Ho M, et al.: Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008, 8:984–989.PubMedCrossRef

15.

Opelz G, Dohler B: Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004, 4:222–230.PubMedCrossRef

16.

Dharnidharka VR, Sullivan EK, Stablein DM, et al.: Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001, 71:1065–1068.PubMedCrossRef

17.

Cockfield SM: Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001, 3:70–78.PubMedCrossRef

18.

Tsai DE, Hardy CL, Tomaszewski JE, et al.: Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001, 71:1076–1088.PubMedCrossRef

19.

Caillard S, Dharnidharka V, Agodoa L, et al.: Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005, 80:1233–1243.PubMedCrossRef

20.

Oton AB, Wang H, Leleu X, et al.: Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma 2008, 49:1738–1744.PubMedCrossRef

21.

• Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007, 92:1489–1494. This is a prospective phase 2 trial of single-agent rituximab after failure of RI. The initial ORR was 79% with 34% CR; 3-year OS was approximately 58%.

22.

Penn I, Porat G: Central nervous system lymphomas in organ allograft recipients. Transplantation 1995, 59:240–244.PubMed

23.

• Swerdlow SH CE, Harris NL: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, edn 4. Lyon, France: International Agency for Research on Cancer; 2008. This is an updated comprehensive WHO classification of pathology of PTLD.

24.

•• Knowles DM, Cesarman E, Chadburn A, et al.: Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995, 85:552–565.PubMed

25.

Chadburn A, Cesarman E, Knowles DM: Molecular pathology of posttransplantation lymphoproliferative disorders. Semin Diagn Pathol 1997, 14:15–26.PubMed

26.

Novoa-Takara L, Perkins SL, Qi D, et al.: Histogenetic phenotypes of B cells in posttransplant lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type: solid organ vs hematopoietic stem cell transplantation. Am J Clin Pathol. 2005, 123:104–112.

27.

Djokic M, Le Beau MM, Swinnen LJ, et al.: Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer 2006, 45:313–318.PubMedCrossRef

28.

Rinaldi A, Capello D, Scandurra M, et al.: Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. Br J Haematol. 2010, 149:569–577.PubMedCrossRef

29.

Johnson LR, Nalesnik MA, Swerdlow SH: Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study. Am J Surg Pathol 2006, 30:1604–1612.PubMedCrossRef

30.

Craig FE, Johnson LR, Harvey SA, et al.: Gene expression profiling of Epstein-Barr viruspositive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders. Diagn Mol Pathol 2007, 16:158–168.PubMedCrossRef

31.

Heslop HE: How I treat EBV lymphoproliferation. Blood 2009, 114:4002–4008.PubMedCrossRef

32.

Starzl TE, Nalesnik MA, Porter KA, et al.: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984, 1:583–587.PubMedCrossRef

33.

Swinnen LJ, Mullen GM, Carr TJ, et al.: Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995, 86:3333–3340.PubMed

34.

Choquet S, Leblond V, Herbrecht R, et al.: Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006, 107:3053–3057.PubMedCrossRef

35.

Benkerrou M, Jais JP, Leblond V, et al.: Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998, 92:3137–3147.PubMed

36.

Davis CL, Wood BL, Sabath DE, et al.: Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998, 66:1770–1779.PubMedCrossRef

37.

Haddad E, Paczesny S, Leblond V, et al.: Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001, 97:1590–1597.PubMedCrossRef

38.

Choquet S, Trappe R, Leblond V, et al.: CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007, 92:273–274.PubMedCrossRef

39.

Fohrer C, Caillard S, Koumarianou A, et al.: Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol 2006, 134:602–612.PubMedCrossRef

40.

Pirsch JD, Stratta RJ, Sollinger HW, et al.: Treatment of severe Epstein-Barr virusinduced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med 1989, 86:241–244.PubMedCrossRef

41.

Schmidt W, Anagnostopoulos I, Scherubl H: Virostatic therapy for advanced lymphoproliferation associated with the Epstein-Barr virus in an HIV-infected patient. N Engl J Med 2000, 342:440–441.PubMedCrossRef

42.

Oertel SH, Ruhnke MS, Anagnostopoulos I, et al.: Treatment of Epstein-Barr virusinduced posttransplantation lymphoproliferative disorder with foscarnet alone in an adult after simultaneous heart and renal transplantation. Transplantation 1999, 67:765–767.PubMedCrossRef

43.

Funch DP, Walker AM, Schneider G, et al.: Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005, 5:2894–2900.PubMedCrossRef

44.

McDiarmid SV, Jordan S, Kim GS, et al.: Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998, 66:1604–1611.PubMedCrossRef

45.

Buell JF, Gross TG, Hanaway MJ, et al.: Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc 2005, 37:954–955.PubMedCrossRef

46.

Caillard S, Lelong C, Pessione F, Moulin B: Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 2006, 6:2735–2742.PubMedCrossRef

47.

• Cavaliere R, Petroni G, Lopes MB, Schiff D: Primary central nervous system posttransplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 2010, 116:863–870. This is an analysis of 34 primary CNS PTLD patients treated over a 25-year period. Median OS was 47 months. Treatment with aggressive therapy, similar to immunocompetent primary CNS, is recommended (eg, high-dose methotrexate-based therapy).

48.

Choquet S OS, Anagnostopoulos I, et al.: Results of the largest study on post-transplantlymphoproliferations (PTLDs) of the central nervous system (CNS) in the rituximab era: a surprising overrepresentation of kidney transplantations, key importance of methotrexate, cytarabine and radiotherapy for long term survival and low impact of rituximab. Blood (ASH Annual Meeting Abstracts) 2008, 3614.

49.

Evens AM, Smith SM: Reply to D. Dierickx et al. J Clin Oncol 2010, In press.

50.

Moise L MC, Pilorge S, et al.: High-dose methotrexate and cytarabine chemotherapy may be effective and safe in solid organ transplant recipients with primary CNS lymphomas (PCNSL). Blood (ASH Annual Meeting Abstracts) 2008, 3611.

51.

Taj MM, Messahel B, Mycroft J, et al.: Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. Br J Haematol 2008, 140:191–196.PubMedCrossRef

52.

Nalesnik MA, Rao AS, Furukawa H, et al.: Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997, 63:1200–1205.PubMedCrossRef

53.

Fujita Y, Rooney CM, Heslop HE: Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant 2008, 41:193–198.PubMedCrossRef

54.

Moosmann A, Bigalke I, Tischer J, et al.: Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010, 115:2960–2970.PubMedCrossRef

55.

•• Haque T, Wilkie GM, Jones MM, et al.: Allogeneic cytotoxic T-cell therapy for EBVpositive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110:1123–1131. This multicenter study used EBV-specific partial allogeneic-matched cytotoxic T cells generated from EBV-positive donors for the treatment of EBV-positive PTLD. ORR at 6 months was 52%, including 42% CR rate. Therapy was overall well-tolerated.

56.

Brewin J, Mancao C, Straathof K, et al.: Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood 2009, 114:4792–4803.PubMedCrossRef

57.

De Angelis B, Dotti G, Quintarelli C, et al.: Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 2009, 114:4784–4791.PubMedCrossRef

58.

Mentzer SJ, Perrine SP, Faller DV: Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis 2001, 3:177–185.PubMedCrossRef

59.

• Perrine SP, Hermine O, Small T, et al.: A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007, 109:2571–2578. This is a prospective clinical trial using concurrent ganciclovir and arginine butyrate therapy; the latter was utilized in order to upregulate thymidine kinase. An ongoing related clinical trial is referenced below.

60.

ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00992732?term=arginine+butyrate&rank=5. Accessed August 2010.

61.

Majewski M, Korecka M, Kossev P, et al.: The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 2000, 97:4285–4290.PubMedCrossRef

62.

Smith SM, van Besien K, Karrison T et al.: Temsirolimus Has Activity in Non-Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium. J Clin Oncol. 2010 Sep 13. [Epub ahead of print].

63.

Kirk AD, Cherikh WS, Ring M, et al.: Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007, 7:2619–2625.PubMedCrossRef

64.

Ghobrial IM, Habermann TM, Ristow KM, et al.: Prognostic factors in patients with posttransplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005, 46:191–196.PubMedCrossRef

65.

Jain AB, Marcos A, Pokharna R, et al.: Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 2005, 80:1692–1698.PubMedCrossRef

Title: Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy
Authors: Andrew M. Evens
Rupali Roy
Danielle Sterrenberg
Michelle Z. Moll
Amy Chadburn
Leo I. Gordon
Publication date: 01-11-2010
Publisher: Current Science Inc.
Published in: Current Oncology Reports / Issue 6/2010
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-010-0132-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2010

Is Maintenance Rituximab Now Ready for PRIMA-Time?

Can Anthracycline Therapy for Pediatric Malignancies Be Less Cardiotoxic?

Should Eligible Patients with T-Cell Lymphoma Receive High-Dose Therapy and Autologous Stem Cell Transplant in the Upfront Setting?

Childhood Rhabdomyosarcoma: New Insight on Biology and Treatment

Maintenance Chemotherapy: An Evolving and Increasingly Acceptable Strategy in Cancer Management

Maintenance and Consolidation Strategies in Non-Hodgkin’s Lymphoma: A Review of the Data

Keynote webinar | Spotlight on antibody–drug conjugates in cancer